Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902116 | 0.91 | ACHE (0.40) | ACHEALDH1A1L3MBTL1KDM4EMEN1 | |
| SCHEMBL11903090 | 0.83 | ALDH1A1 (0.41) | SMN1; SMN2ACHEGSK3BALDH1A1L3MBTL1 | |
| SCHEMBL11903055 | 0.77 | HTT (0.42) | SMN1; SMN2GSK3BALDH1A1KDM4EMEN1 | |
| SCHEMBL11903193 | 0.76 | HTT (0.41) | SMN1; SMN2GSK3BALDH1A1KDM4EMEN1 | |
| SCHEMBL11918131 | 0.74 | ACHE (0.41) | SMN1; SMN2ACHEGSK3BALDH1A1L3MBTL1 | |
| SCHEMBL1609556 | 0.74 | KDM4E (0.43) | SMN1; SMN2GSK3BALDH1A1L3MBTL1KDM4E | |
| SCHEMBL11902809 | 0.72 | ALDH1A1 (0.42) | SMN1; SMN2ACHEALDH1A1L3MBTL1KDM4E | |
| SCHEMBL11913410 | 0.71 | PRKCQ (0.41) | SMN1; SMN2ALDH1A1L3MBTL1KDM4EMEN1 | |
| SCHEMBL11902749 | 0.71 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1L3MBTL1KDM4EMEN1 | |
| SCHEMBL1609455 | 0.70 | KMT2A (0.39) | SMN1; SMN2ALDH1A1L3MBTL1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202690-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202690-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011045561-A2 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202690-A1 | HERBICIDAL COMPOUNDS | DDT, HAO2, HAAO | SMN1; SMN2 3709/4885ACHE 225/4885GSK3B 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.